BACKGROUND: More than 11 000 @entity1 are examined for possible @entity989 in Germany each year, and 2-5% of them are treated for it. Even though screening and treatment programs are in place, the affected @entity1 can still suffer @entity227 . METHODS: In this article, we summarize the pathogenesis, screening, and treatment of @entity989 on the basis of a selective review of pertinent literature, retrieved by a PubMed search. The article centers on publications from 2011 to 2015 on the new option of treatment with @entity7 inhibitors and discusses it in comparison to laser therapy. RESULTS: All premature neonates with a low gestational age at birth, low birth weight, or prolonged exposure to supplemental @entity26 must undergo screening by an ophthalmologist. Laser therapy is effective for stages 1-3 and for @entity146 posterior @entity989 . Its disadvantages are the induction of @entity2318 and the development of severe @entity1714 in 17-40% of the @entity1 so treated. Anti- @entity7 treatment ( @entity7 = vascular endothelial growth factor) does not induce any visible @entity2318 and seems to cause less @entity1714 , but long-term data on safety, dosing, and the choice of anti- @entity7 drug are still lacking. CONCLUSION: The available evidence for anti- @entity7 treatment is on a much lower level than the evidence for laser therapy. Anti- @entity7 may be a way to avoid the disadvantages of laser therapy ( @entity2318 and severe @entity1714 ). Unlike laser therapy, however, the intravitreal injection of @entity7 inhibitors may suppress systemic @entity7 levels and potentially harm the developing brain, lungs, or other organs. The currently open questions about anti- @entity7 treatment concern its dosing, choice of drug, and long-term safety.

Screening and Treatment in XXXX .

@entity1 :: ('9606', 'Species') :: ['children'] @entity227 :: ('MESH:D014786', 'Disease') :: ['visual impairment'] @entity7 :: ('7422', 'Gene') :: ['VEGF'] @entity146 :: ('MESH:D001523', 'Disease') :: ['aggressive'] @entity2318 :: ('MESH:D002921', 'Disease') :: ['scarring'] @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen'] @entity989 :: ('MESH:D012164', 'Disease') :: ['retinopathy of prematurity'] @entity1714 :: ('MESH:D009216', 'Disease') :: ['myopia']
@entity989 :: (MESH:D012164,Disease) :: ['Retinopathy of Prematurity']
